BRICKELL BIOTECH INC BBI 深 滬
等待開盤 08-15 09:30:00 美东时间
2.35
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.35
- 總市值 675.39万
- 52周最高 36.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.21
- 委 比 0.00%
- 總股本 287.40万
- 歷史最高 225.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.185
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
<p>BridgeBio Oncology Therapeutics, Inc. (BBOT) completed its business combination with Helix Acquisition Corp. II on August 11, 2025, closing a $261 million PIPE led by Cormorant Asset Management. Combining this with $120 million from the Helix trust account, BBOT secured approximately $382 million in gross proceeds to advance its RAS-targeted oncology pipeline. BBOT will begin trading on the Nasdaq Global Market under the ticker "BBOT" on Augus...
08-11 20:30
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
08-05 11:00
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
2022-06-30 16:55
Brickell Biotech开始进行特应性皮炎治疗的第一阶段试验
09:49 AM EDT, 05/19/2022 (MT Newswires) -- Brickell Biotech (BBI) said Thursday...
2022-05-19 21:54
Brickell Biotech Doses First Subject In Phase 1 Study Of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from
2022-05-19 20:04
Lake Street Downgrades Brickell Biotech to Hold
Lake Street analyst Thomas Flaten downgrades Brickell Biotech (NASDAQ:BBI) from Buy to Hold.
2022-05-13 21:31
奥本海默将Brickell Biotech的目标价从4美元调整为1美元，维持强于大盘的评级
09:02 AM EDT, 05/13/2022 (MT Newswires) -- (MT Newswires covers equity, commodi...
2022-05-13 21:16
